United Therapeutics Corporation (NASDAQ:UTHR) Files An 8-K Other Events
Item 8.01. Other Events.
On April8, 2019, United Therapeutics Corporation issued a press release announcing that its BEAT study of esuberaprost did not meet its primary endpoint. A copy of the press release is attached hereto as Exhibit99.1 and incorporated herein by reference.
Item 9.01. Exhibits
(d) Exhibits
|
ExhibitNo. |
DescriptionofExhibit |
|
99.1 |
Press Release dated April8, 2019 |
UNITED THERAPEUTICS Corp Exhibit
EX-99.1 2 a19-7981_1ex99d1.htm EX-99.1 Exhibit 99.1 Contact: James Edgemond Phone: (301) 608-9292 E-mail: jedgemond@unither.com UNITED THERAPEUTICS ANNOUNCES BEAT STUDY OF ESUBERAPROST DOES NOT MEET PRIMARY ENDPOINT Silver Spring,…
To view the full exhibit click here
About United Therapeutics Corporation (NASDAQ:UTHR)
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb). Its Prostacyclin Analogues lead product is Remodulin (treprostinil) Injection. It also includes Tyvaso (treprostinil) Inhalation Solution and Orenitram (treprostinil) Extended-Release Tablets. Its subsidiary is developing another oral prostacyclin analogue for the treatment of pulmonary arterial hypertension (PAH) called esuberaprost. Its PDE-5 inhibitor is Adcirca (tadalafil) tablets are indicated for the treatment of PAH. Its Unituxin (dinutuximab) Injection in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and 13-cis-retinoic acid is indicated for the treatment of pediatric patients with neuroblastoma.